Treatment of tumors using specific anti-L1 antibody

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9260521
APP PUB NO 20140120117A1
SERIAL NO

14045019

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDIGENE AGLOCHHAMER STR 11 PLANEGG MARTINSRIED 82152

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Altevogt, Peter Neckargemuend, DE 31 200
Baerreiter, Silke Weinheim, DE 1 2
Breitling, Frank Heidelberg, DE 16 258
Kelm, Daniela Steinheim an der Murr, DE 4 6
Krueger, Achim Munich, DE 2 2
Li, Yi Wantage, GB 917 5421
Luettgau, Sandra Schongau, DE 2 2
Moebius, Ulrich Gauting, DE 21 68
Moldenhauer, Gerhard Bad Arolsen, DE 14 145
Schaefer, Heiner Kiel, DE 10 20
Sebens, Susanne Kiel, DE 2 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 16, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00